FDA issues draft guidance on marketing submissions for AI-enabled medical devices
The Food and Drug Administration issued draft guidance Jan. 6 on marketing submissions and lifecycle management for artificial intelligence-enabled devices. The guidance clarifies differences in terminology between the FDA and the AI device manufacturers and software developers. In addition, it provides recommendations on information needed throughout a product's life cycle for regulation of safety and efficacy.
Related News Articles
Headline
In this conversation, John Riggi, AHA national advisor for cybersecurity and risk, and Scott Gee, AHA deputy national advisor for cybersecurity and risk, break…
Headline
The AHA has released a fact sheet explaining how artificial intelligence tools help alleviate administrative burden for providers, particularly in areas such…
Headline
The Food and Drug Administration is seeking public feedback on a discussion paper released today on potential regulatory approaches for generative artificial…
Headline
The AHA Aug. 13 responded to a Food and Drug Administration request for input on the risks and benefits to health and safety associated with non-device…
Headline
The Common Health Coalition announced Aug. 13 that it will receive $100 million in funding from the OpenAI Foundation for a new initiative using artificial…
Headline
The AHA’s American Organization for Nursing Leadership will host a webinar Aug. 5 at noon ET on how nurse leaders can guide ambient documentation from pilot…